Aubrai is a decentralized AI agent that aims to revolutionize longevity research by leveraging blockchain and decentralized autonomous organizations (DAOs) for scientific funding.
Key Highlights:
- Aubrai’s AUBRAI token enables holders to influence research funding and share in the revenue from discoveries.
- It combines AI with human expertise to catalyze breakthroughs in aging research, presenting an innovative alternative to traditional funding mechanisms.
Aubrai was launched this week within the Bio Protocol, showcasing the intersection of longevity research and cryptocurrency. Decentralized science (DeSci) aims to directly fund experiments while ensuring transparent attribution and turning research outputs into tradeable tokenized assets.
The AUBRAI token makes holders permanent stakeholders in research outputs, with governance over funding choices and shared profits from discoveries.
Developed by VitaDAO and Bio Protocol alongside Aubrey de Grey’s LEV Foundation, Aubrai seeks to overcome the ‘valley of death’ in research where innovative projects suffer due to lack of funding.
As de Grey states, “The consequences of traditional financing are a chronic funding gap, over-reliance on philanthropy, and a ‘valley of death’ between discovery and the clinic.” He advocates for alternative mechanisms like DAOs, longevity-focused venture funds, and DeSci platforms that can address long-term horizons and align incentives for social benefit.
Aubrai’s strategy incorporates unpublished lab data from de Grey’s research, which provides unique insights beyond existing literature, enhancing its competitive advantage in generating commercially viable hypotheses.
The agent utilizes a knowledge graph to ingest experiments, propose hypotheses, and manage funding based on token-holder votes. According to de Grey, “We are already seeing the agent generate intriguing new hypotheses and suggest actionable steps.”
Validated experiments result in IP-tokens that can be licensed to pharmaceutical firms, with proceeds returning to researchers and contributing partners.
Aubrai also implements recommendations in ongoing studies, optimizing methodologies through advanced insights, marking a shift in scientific funding and collaboration in the longevity sector.
However, while promising, such decentralized projects may face regulatory scrutiny concerning tokenized intellectual properties and resistance from established pharmaceutical entities.
Ultimately, if successful, Aubrai could showcase the ability of blockchain technology to not only enhance research infrastructure but also significantly advance the field of longevity toward therapeutic applications.
